The companies announced last July that they plan to combine Mylan with Upjohn to create a global pharmaceutical giant producing both generic and brand-name drugs. The drugmakers said last November they plan to call the combined company Viatris.
Due to delays in the regulatory review process caused by the COVID-19 pandemic, Mylan said it’s pushing back the meeting for shareholders to approve the deal from April 27 to June 30.
The drugmaker said the companies aren’t changing any terms of the deal.
Read the full news release here.
More articles on pharmacy:
Gilead asks FDA to take back orphan drug status for COVID-19 drug
Walmart nearly criminally charged over opioid prescriptions, report finds
13 drugmakers form consortium to find COVID-19 treatments
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
